Perugia, Italy – April 26, 2016.
During the 7th BioinItaly investment forum & Intesa San Paolo startup initiative on 19th April, 2016. In Milan (Italy) Plasfer was selected between 14 finalists from 100 Biotech&Healthcare companies coming from Italy.
Plasfer received one of two special prizes assigned during the final, the Novartis Oncology Award.
Marco Malvestiti – CEO – said: “ It was a great pleasure for us to receive the Novartis Oncology Award, demonstrating the big importance of our project and our company.
During the final, we had the possibility to meet and to start a dialogue with big pharma companies and famous venture firms that are interested to Plasfer.”
Plasfer srls is a pre-clinical stage biopharmaceutical company, based in Umbria (Italy) specialized in the development of delivery of RNA-based drug with platelets using a proprietary medical technology.
For further information, please contact: email@example.com